Federal Rescheduling in 2026: What the April Schedule III Order Does — and Doesn't — Do
On April 23, 2026, the U.S. Department of Justice issued a final order reclassifying two specific categories to Schedule III of the Controlled Substances Act: marijuana contained in an FDA-approved drug product, and marijuana subject to a qualifying state medical-marijuana license. This is a notable but narrow change. All other cannabis — including adult-use (recreational) cannabis not covered by those categories — remains in Schedule I. This page is educational only and does not facilitate the sale, possession, or distribution of cannabis.
For patients, it is important to understand what rescheduling is not. It does not make state-authorized cannabis products FDA-approved medicines, it does not create a federal prescribing pathway at the pharmacy counter, and it does not erase the differences between federal and California law. A separate DEA administrative hearing was scheduled in mid-2026 to consider broader rescheduling questions, and the timing and outcome of any further action can change.
Cannabis is not FDA-approved to diagnose, treat, cure, or prevent any disease. Anyone considering medical cannabis should consult a licensed healthcare provider about their condition, medications, and possible interactions, and should verify current rules with official sources.
To put dates on it: the Justice Department’s final order was signed on April 22, 2026 and published in the Federal Register on April 28, 2026, moving two narrow categories — FDA-approved marijuana drug products and cannabis handled under a state medical-marijuana license — from Schedule I to Schedule III. It is a conditional, targeted change rather than a blanket reclassification, and the DEA opened a separate expedited hearing on June 29, 2026 to weigh whether marijuana as a whole should follow. For California patients the practical takeaway has not changed: Schedule III is not legalization, it does not put cannabis on a pharmacy shelf, and your state program’s rules, physician recommendations, and dispensary requirements still govern lawful access. We track every step so our patient guidance reflects the law as it actually reads today.
Sources: Federal Register — Rescheduling of FDA-approved marijuana products (Apr 2026); DEA — Marijuana Rescheduling Regulatory Actions; Federal Register — Rescheduling of Marijuana (Apr 2026)
